Galectin-9  ||| S:0 E:11 ||| NNP
suppresses  ||| S:11 E:22 ||| VBD
the  ||| S:22 E:26 ||| DT
proliferation  ||| S:26 E:40 ||| NN
of  ||| S:40 E:43 ||| IN
gastric  ||| S:43 E:51 ||| JJ
cancer  ||| S:51 E:58 ||| NN
cells  ||| S:58 E:64 ||| NNS
in  ||| S:64 E:67 ||| IN
vitro  ||| S:67 E:73 ||| JJ
Gastric  ||| S:73 E:81 ||| JJ
cancer  ||| S:81 E:88 ||| NN
is  ||| S:88 E:91 ||| VBZ
the  ||| S:91 E:95 ||| DT
second-leading  ||| S:95 E:110 ||| JJ
cause  ||| S:110 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
cancer-related  ||| S:119 E:134 ||| JJ
mortality  ||| S:134 E:144 ||| NN
worldwide ||| S:144 E:153 ||| NN
,  ||| S:153 E:155 ||| ,
and  ||| S:155 E:159 ||| CC
the  ||| S:159 E:163 ||| DT
prognosis  ||| S:163 E:173 ||| NN
of  ||| S:173 E:176 ||| IN
advanced  ||| S:176 E:185 ||| JJ
gastric  ||| S:185 E:193 ||| JJ
cancer  ||| S:193 E:200 ||| NN
remains  ||| S:200 E:208 ||| VBZ
poor ||| S:208 E:212 ||| JJ
.  ||| S:212 E:214 ||| .
Galectin-9  ||| S:214 E:225 ||| NNP
( ||| S:225 E:226 ||| -LRB-
Gal-9 ||| S:226 E:231 ||| NNP
)  ||| S:231 E:233 ||| -RRB-
is  ||| S:233 E:236 ||| VBZ
a  ||| S:236 E:238 ||| DT
tandem-repeat-type  ||| S:238 E:257 ||| JJ
galectin  ||| S:257 E:266 ||| NN
that  ||| S:266 E:271 ||| WDT
has  ||| S:271 E:275 ||| VBZ
recently  ||| S:275 E:284 ||| RB
been  ||| S:284 E:289 ||| VBN
demonstrated  ||| S:289 E:302 ||| VBN
to  ||| S:302 E:305 ||| TO
exert  ||| S:305 E:311 ||| VB
anti-proliferative  ||| S:311 E:330 ||| JJ
effects  ||| S:330 E:338 ||| NNS
on  ||| S:338 E:341 ||| IN
various  ||| S:341 E:349 ||| JJ
types  ||| S:349 E:355 ||| NNS
of  ||| S:355 E:358 ||| IN
cancer  ||| S:358 E:365 ||| NN
cells ||| S:365 E:370 ||| NNS
.  ||| S:370 E:372 ||| .
The  ||| S:372 E:376 ||| DT
aim  ||| S:376 E:380 ||| NN
of  ||| S:380 E:383 ||| IN
our  ||| S:383 E:387 ||| PRP$
present  ||| S:387 E:395 ||| JJ
study  ||| S:395 E:401 ||| NN
was  ||| S:401 E:405 ||| VBD
to  ||| S:405 E:408 ||| TO
evaluate  ||| S:408 E:417 ||| VB
the  ||| S:417 E:421 ||| DT
effects  ||| S:421 E:429 ||| NNS
of  ||| S:429 E:432 ||| IN
Gal-9  ||| S:432 E:438 ||| CD
on  ||| S:438 E:441 ||| IN
human  ||| S:441 E:447 ||| JJ
gastric  ||| S:447 E:455 ||| JJ
cancer  ||| S:455 E:462 ||| NN
cells  ||| S:462 E:468 ||| NNS
and  ||| S:468 E:472 ||| CC
the  ||| S:472 E:476 ||| DT
expression  ||| S:476 E:487 ||| NN
levels  ||| S:487 E:494 ||| NNS
of  ||| S:494 E:497 ||| IN
microRNAs  ||| S:497 E:507 ||| NNP
( ||| S:507 E:508 ||| -LRB-
miRNAs ||| S:508 E:514 ||| NNP
)  ||| S:514 E:516 ||| -RRB-
associated  ||| S:516 E:527 ||| VBN
with  ||| S:527 E:532 ||| IN
the  ||| S:532 E:536 ||| DT
antitumor  ||| S:536 E:546 ||| JJ
effects  ||| S:546 E:554 ||| NNS
of  ||| S:554 E:557 ||| IN
Gal-9  ||| S:557 E:563 ||| CD
in vitro ||| S:563 E:571 ||| CD
.  ||| S:571 E:573 ||| .
In  ||| S:573 E:576 ||| IN
our  ||| S:576 E:580 ||| PRP$
initial  ||| S:580 E:588 ||| JJ
experiments ||| S:588 E:599 ||| NNS
,  ||| S:599 E:601 ||| ,
Gal-9  ||| S:601 E:607 ||| NNP
suppressed  ||| S:607 E:618 ||| VBD
the  ||| S:618 E:622 ||| DT
proliferation  ||| S:622 E:636 ||| NN
of  ||| S:636 E:639 ||| IN
gastric  ||| S:639 E:647 ||| JJ
cancer  ||| S:647 E:654 ||| NN
cell  ||| S:654 E:659 ||| NN
lines  ||| S:659 E:665 ||| NNS
in vitro ||| S:665 E:673 ||| VBP
.  ||| S:673 E:675 ||| .
Our  ||| S:675 E:679 ||| PRP$
data  ||| S:679 E:684 ||| NNS
further  ||| S:684 E:692 ||| RB
revealed  ||| S:692 E:701 ||| VBN
that  ||| S:701 E:706 ||| IN
Gal-9  ||| S:706 E:712 ||| NNP
increased  ||| S:712 E:722 ||| VBD
caspase-cleaved  ||| S:722 E:738 ||| NNP
keratin 18  ||| S:738 E:749 ||| NNP
( ||| S:749 E:750 ||| -LRB-
CCK18 ||| S:750 E:755 ||| NNP
)  ||| S:755 E:757 ||| -RRB-
levels  ||| S:757 E:764 ||| NNS
in  ||| S:764 E:767 ||| IN
gastric  ||| S:767 E:775 ||| JJ
cancer  ||| S:775 E:782 ||| NN
cells ||| S:782 E:787 ||| NNS
.  ||| S:787 E:789 ||| .
Additionally ||| S:789 E:801 ||| RB
,  ||| S:801 E:803 ||| ,
Gal-9  ||| S:803 E:809 ||| NNP
reduced  ||| S:809 E:817 ||| VBD
the  ||| S:817 E:821 ||| DT
phosphorylation  ||| S:821 E:837 ||| NN
of  ||| S:837 E:840 ||| IN
vascular  ||| S:840 E:849 ||| JJ
endothelial  ||| S:849 E:861 ||| JJ
growth  ||| S:861 E:868 ||| NN
factor  ||| S:868 E:875 ||| NN
receptor-3  ||| S:875 E:886 ||| NNP
( ||| S:886 E:887 ||| -LRB-
VEGFR-3 ||| S:887 E:894 ||| NNP
)  ||| S:894 E:896 ||| -RRB-
and  ||| S:896 E:900 ||| CC
insulin-like  ||| S:900 E:913 ||| JJ
growth  ||| S:913 E:920 ||| NN
factor-1  ||| S:920 E:929 ||| CD
receptor  ||| S:929 E:938 ||| NN
( ||| S:938 E:939 ||| -LRB-
IGF-1R ||| S:939 E:945 ||| NNP
) ||| S:945 E:946 ||| -RRB-
.  ||| S:946 E:948 ||| .
Furthermore ||| S:948 E:959 ||| RB
,  ||| S:959 E:961 ||| ,
miRNA  ||| S:961 E:967 ||| JJ
expression  ||| S:967 E:978 ||| NN
levels  ||| S:978 E:985 ||| NNS
were  ||| S:985 E:990 ||| VBD
markedly  ||| S:990 E:999 ||| RB
altered  ||| S:999 E:1007 ||| VBN
with  ||| S:1007 E:1012 ||| IN
Gal-9  ||| S:1012 E:1018 ||| CD
treatment  ||| S:1018 E:1028 ||| NN
in vitro ||| S:1028 E:1036 ||| NN
.  ||| S:1036 E:1038 ||| .
In  ||| S:1038 E:1041 ||| IN
conclusion ||| S:1041 E:1051 ||| NN
,  ||| S:1051 E:1053 ||| ,
Gal-9  ||| S:1053 E:1059 ||| NNP
suppressed  ||| S:1059 E:1070 ||| VBD
the  ||| S:1070 E:1074 ||| DT
proliferation  ||| S:1074 E:1088 ||| NN
of  ||| S:1088 E:1091 ||| IN
human  ||| S:1091 E:1097 ||| JJ
gastric  ||| S:1097 E:1105 ||| JJ
cancer  ||| S:1105 E:1112 ||| NN
cells  ||| S:1112 E:1118 ||| NNS
by  ||| S:1118 E:1121 ||| IN
inducing  ||| S:1121 E:1130 ||| JJ
apoptosis ||| S:1130 E:1139 ||| NN
.  ||| S:1139 E:1141 ||| .
These  ||| S:1141 E:1147 ||| DT
findings  ||| S:1147 E:1156 ||| NNS
suggest  ||| S:1156 E:1164 ||| VBP
that  ||| S:1164 E:1169 ||| IN
Gal-9  ||| S:1169 E:1175 ||| NNP
could  ||| S:1175 E:1181 ||| MD
be  ||| S:1181 E:1184 ||| VB
a  ||| S:1184 E:1186 ||| DT
potential  ||| S:1186 E:1196 ||| JJ
therapeutic  ||| S:1196 E:1208 ||| JJ
target  ||| S:1208 E:1215 ||| NN
in  ||| S:1215 E:1218 ||| IN
the  ||| S:1218 E:1222 ||| DT
treatment  ||| S:1222 E:1232 ||| NN
of  ||| S:1232 E:1235 ||| IN
gastric  ||| S:1235 E:1243 ||| JJ
cancer ||| S:1243 E:1249 ||| NN
.  ||| S:1249 E:1251 ||| .
